Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (171-180 of 177) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 177 results.
Cell Death & Disease|June 2, 2017
Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular unitsJing Zou, Zhaoyu Chen, Xiaobo Wei, et al.
European Journal of Neurology|February 9, 2023
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's diseaseValentina Leta, Lisa Klingelhoefer, Katherine Longardner, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Novel pharmacological targets for the treatment of Parkinson's diseaseAnthony H V Schapira, Erwan Bezard, Jonathan Brotchie, et al.
Journal of Neuropathology and Experimental Neurology|May 8, 2007
The etiopathogenesis of Parkinson disease and suggestions for future research. Part IIIrene Litvan, Marie-Francoise Chesselet, Thomas Gasser, et al.
Journal of Neuropathology and Experimental Neurology|April 7, 2007
The etiopathogenesis of Parkinson disease and suggestions for future research. Part IIrene Litvan, Glenda Halliday, Mark Hallett, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 17, 2004
Levodopa in the treatment of Parkinson's disease: current controversiesC Warren Olanow, Yves Agid, Yoshi Mizuno, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2023
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and ProposalsStefanie T Jost, Marie-Ann Kaldenbach, Angelo Antonini, et al.
Pageof 18

Showing results (171-180 of 177) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 177 results.
Cell Death & Disease|June 2, 2017
Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular unitsJing Zou, Zhaoyu Chen, Xiaobo Wei, et al.
European Journal of Neurology|February 9, 2023
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's diseaseValentina Leta, Lisa Klingelhoefer, Katherine Longardner, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Novel pharmacological targets for the treatment of Parkinson's diseaseAnthony H V Schapira, Erwan Bezard, Jonathan Brotchie, et al.
Journal of Neuropathology and Experimental Neurology|May 8, 2007
The etiopathogenesis of Parkinson disease and suggestions for future research. Part IIIrene Litvan, Marie-Francoise Chesselet, Thomas Gasser, et al.
Journal of Neuropathology and Experimental Neurology|April 7, 2007
The etiopathogenesis of Parkinson disease and suggestions for future research. Part IIrene Litvan, Glenda Halliday, Mark Hallett, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 17, 2004
Levodopa in the treatment of Parkinson's disease: current controversiesC Warren Olanow, Yves Agid, Yoshi Mizuno, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2023
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and ProposalsStefanie T Jost, Marie-Ann Kaldenbach, Angelo Antonini, et al.
Pageof 18